Recent Updates
Recently added Catalysts

5% minoxidil foam

Phase 3

Androgenetic Alopecia | Small molecule | Dermatology |Sunshine Biopharma Inc.|Last Updated: Mar 5, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment294

FDA Designations

No designations recorded

Clinical trial landscape

5% minoxidil foam · 1 trial · 1 indication

Phase 3 1
NCT07080931Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic AlopeciaAndrogenetic Alopecia
RECRUITING294 Analytics
PHASE3RECRUITING
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
Androgenetic Alopecia
NCT07080931294
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change from baseline in Target Area Hair Count (TAHC) at Week 24, assessed via digital phototrichogram analysis in trial participa
Week 24

Secondary Endpoints

Mean change from baseline in Target Area Hair Count (TAHC) at Weeks 6, 12, and 18
Weeks 6, 12, and 18
Percent change from baseline in Target Area Hair Count (TAHC) at Weeks 12 and 24
Weeks 12 , 24
Self-assessed satisfaction scores at Weeks 6, 12, 18, and 24
Weeks 6, 12, 18, 24
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
5% Minoxidil FoamEXPERIMENTAL -
Placebo for 5% Minoxidil FoamPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
5% minoxidil foamDRUGTrial participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
Placebo for 5% Minoxidil FoamDRUGTrial participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Voluntarily participate in the study and be able to provide a written Informed Consent Form (ICF); * Female aged ≥ 18 years; * Investigator-diagnosed androgenetic alopecia; * Hair loss severity graded D3 to D6 on the Savin scale; * Willingness to maintain identical hairstyle, ...

Countries:China
Unlock Eligibility Criteria

Frequently asked questions about 5% minoxidil foam

What is 5% minoxidil foam used for?

5% minoxidil foam is used for the treatment of androgenetic alopecia, a common form of hair loss. It is being developed as a topical foam formulation for this condition. The drug is currently in Phase 3 clinical development for this indication.

Who makes 5% minoxidil foam?

5% minoxidil foam is being developed by Sunshine Biopharma Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the efficacy and safety of this drug for the treatment of androgenetic alopecia.

What phase is 5% minoxidil foam in?

5% minoxidil foam is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is recruiting participants to assess its efficacy and safety in treating androgenetic alopecia.

What clinical trials is 5% minoxidil foam in?

5% minoxidil foam is being evaluated in a Phase 3 clinical trial with the identifier NCT07080931. This randomized, double-blind, placebo-controlled study is assessing the efficacy and safety of 5% minoxidil foam in female androgenetic alopecia. The trial is recruiting 294 participants in China.

Is 5% minoxidil foam the same as minoxidil?

5% minoxidil foam is a formulation of minoxidil, a small molecule used to treat hair loss. The drug is being developed specifically as a 5% foam formulation for androgenetic alopecia. It is currently in Phase 3 clinical trials to evaluate its efficacy and safety.